ETARACIZUMAB: A DEEP ANALYSIS INTO MEDI523 AND LM609

Etaracizumab, formerly known as MEDI523 and subsequently LM609, represents a promising strategy in antibody-mediated therapy. This humanized protein is intended to specifically neutralize the activity of complement factor , a vital component of the complement system involved in tissue damage. Da